Why Elevance Health (ELV) Is Getting Attention Now
Recent commentary on Elevance Health (ELV) highlights strong past share returns, along with a current valuation discount versus peers and fair value benchmarks. This combination is putting fresh attention on the stock’s risk and reward profile.
Over the past year Elevance Health has coupled a strong 1 year total shareholder return of 32.66% with a 15.03% year to date share price return. Despite a recent 1 day share price decline of 1.76% to US$407.50, momentum over the past month remains positive. This keeps recent leadership changes and AI initiatives framed against a valuation that still screens as discounted versus peers and fair value benchmarks.
Scan for other stocks showing a similar mix of strong share returns and valuation discounts to Elevance Health by checking our curated 47 high quality undervalued stocks list.
The recent pullback leaves Elevance Health trading around US$407.50, while analyst targets and intrinsic estimates point higher. Where does fair value really sit in that gap between the market price and those ranges of estimates?
Most Popular Narrative: 9.3% Undervalued
The most followed narrative anchors Elevance Health’s fair value at US$449.10, compared with the latest close at US$407.50. That gap rests on a detailed view of earnings power and margin repair.
Demographic shifts, notably the aging U.S. population and increasing chronic disease prevalence, underpin long-term growth opportunities in Medicare Advantage and Medicaid. Elevance's disciplined approach to pricing and rate negotiations, combined with proactive engagement with state partners, is expected to drive sustainable revenue growth and margin recovery in these government-backed segments.
Want to see what this narrative really assumes about Elevance Health? The key is how revenue, margins, and future earnings all line up to justify that fair value. The details behind those projections might surprise you.
Result: Fair Value of $449.10 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Elevance Health still faces pressure from elevated medical costs in ACA and Medicaid, and any prolonged delay in Medicaid rate recovery could weaken the margin recovery story.
Find out about the key risks to this Elevance Health narrative.
Next Steps
Given the mixed sentiment around Elevance Health, it makes sense to look at the underlying data yourself and reach an independent view. To see why some investors are optimistic, review the 4 key rewards.
Looking for more investment ideas beyond Elevance Health?
If Elevance Health has your attention, do not stop there. Broaden your watchlist with other focused ideas that could suit different goals and risk levels.
- Target potential value opportunities by comparing Elevance Health with companies in our curated 47 high quality undervalued stocks, which pair robust fundamentals with discounted prices.
- Prioritise resilience by scanning the list of solid balance sheet and fundamentals (52 results) so you can quickly spot businesses with stronger financial footing than many broad market peers.
- Get ahead of the crowd by reviewing the 19 high quality undiscovered gems before these quieter opportunities attract wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com